{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:04:41Z","timestamp":1782795881697,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012308","name":"National Jewish Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:31:59Z","timestamp":1725633119000},"page":"725-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologics in Asthma"],"prefix":"10.1016","volume":"44","author":[{"suffix":"II","given":"Orlando","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia C.L.","family":"Hoyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2024.08.004_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.08.004_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, asthma, and Immunology, American Academy of Allergy, asthma, and Immunology, and American Thoracic Society Workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2024.08.004_bib5","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.iac.2024.08.004_bib6","first-page":"461","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 - published by the German Respiratory Society (DGP) e. V","volume":"77","author":"Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"issue":"2","key":"10.1016\/j.iac.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2024.08.004_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.congress-2022.2028","article-title":"REDES study: Mepolizumab is effective in patients with severe eosinophilic asthma and Comorbid Nasal Polyps","author":"Arismendi Nunez","year":"2022","journal-title":"Airway Pharmacology and Treatment"},{"key":"10.1016\/j.iac.2024.08.004_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the redes study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iac.2024.08.004_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.congress-2023.PA630","article-title":"Real-world mepolizumab outcomes in severe asthma: Realiti-A post hoc analysis by exacerbation history","author":"Bagnasco","year":"2023","journal-title":"Allerg Immunol (Leipz)"},{"key":"10.1016\/j.iac.2024.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A5985","article-title":"Clinical remission achievement in severe asthma following mepolizumab treatment: results from the Realiti-A study at 2 years. C101","author":"Brusselle","year":"2023","journal-title":"Impact Biologics Asthma Outcomes"},{"issue":"10056","key":"10.1016\/j.iac.2024.08.004_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.iac.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (Calima): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2024.08.004_bib14","author":"Harrison"},{"issue":"1","key":"10.1016\/j.iac.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"2301521","DOI":"10.1183\/13993003.01521-2023","article-title":"Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world xaloc-1 programme","volume":"64","author":"Jackson","year":"2024","journal-title":"Eur Respir j"},{"key":"10.1016\/j.iac.2024.08.004_bib16","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.iac.2024.08.004_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma quest: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.iac.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (traverse): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2024.08.004_bib19","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A5995","article-title":"Dupilumab induces clinical remission in patients with uncontrolled, moderate-to-severe, type 2 inflammatory asthma. C101","author":"Pavord","year":"2023","journal-title":"Impact of Biologics on Asthma Outcomes"},{"issue":"1","key":"10.1016\/j.iac.2024.08.004_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.iac.2024.08.004_bib21","article-title":"On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 navigator study","author":"Castro","year":"2022","journal-title":"Eur Respir Soc"},{"issue":"1","key":"10.1016\/j.iac.2024.08.004_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01503-z","article-title":"Source: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"21","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.iac.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (destination): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.iac.2024.08.004_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.congress-2023.OA1415","article-title":"Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (destination)","author":"Brightling","year":"2023","journal-title":"Airway Pharmacology and Treatment"},{"key":"10.1016\/j.iac.2024.08.004_bib25","doi-asserted-by":"crossref","first-page":"107285","DOI":"10.1016\/j.rmed.2023.107285","article-title":"Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: findings from Chronicle","volume":"216","author":"Panettieri","year":"2023","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.iac.2024.08.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.12.494","article-title":"Clinical remission with biologic use among US subspecialist-treated patients with severe asthma: results from the Chronicle Study","volume":"149","author":"Chipps","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2024.08.004_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.congress-2022.3553","article-title":"Clinical response and remission in patients with severe asthma treated with biologic treatment: findings from the nationwide Danish severe asthma registry","author":"Hansen","year":"2022","journal-title":"Airway Pharmacology and Treatment"},{"key":"10.1016\/j.iac.2024.08.004_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-01065-0","article-title":"International severe asthma registry (ISAR): protocol for a global registry","volume":"20","author":"FitzGerald","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.iac.2024.08.004_bib29","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2024.08.004_bib30","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202405-0894ED","article-title":"Remission in the world of severe asthma","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.iac.2024.08.004_bib31","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.rmed.2024.107528","article-title":"Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy","volume":"222","author":"Breslavsky","year":"2024","journal-title":"Respir Med"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:39:44Z","timestamp":1728391184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000614"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}